Market Place
Sourcing Support
Immatics Announces Q3 2024 Results & First Data on TCER® IMA402
18 Nov 2024 //
GLOBENEWSWIRE
Immatics Announces TCR-T Therapy PRAME Targets at 39th SITC
08 Nov 2024 //
GLOBENEWSWIRE
Immatics leaps into phase 3 on strength of early-stage PFS data
10 Oct 2024 //
FIERCE BIOTECH
Immatics Updates On IMA203 TCR-T In Melanoma And SUPRAME Trial
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Proposed $150 Million Public Offering
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Pricing of $150 Million Public Offering
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Presentations At SITC Annual Meeting 2024
04 Oct 2024 //
GLOBENEWSWIRE
Immatics Presents TCER IMA401 Phase 1 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Bristol Myers axes Immatics` bispecific after $150M bet
16 Sep 2024 //
FIERCE BIOTECH
Immatics To Give Oral Presentation At Melanoma Research Congress 2024
06 Sep 2024 //
GLOBENEWSWIRE
Immatics Announces Second Quarter 2024 Financial Results and Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Immatics Appoints Alise Reicin to Board of Directors
31 Jul 2024 //
GLOBENEWSWIRE
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
18 Jul 2024 //
GLOBENEWSWIRE
Immatics Announces First Quarter 2024 Financial Results and Business Update
14 May 2024 //
GLOBENEWSWIRE
Immatics Announces Full Year 2023 Financial Results and Corporate Update
21 Mar 2024 //
GLOBENEWSWIRE
Immatics Announces Proposed Public Offering
17 Jan 2024 //
GLOBENEWSWIRE
Immatics Announces Pricing of $175 Million Public Offering
17 Jan 2024 //
GLOBENEWSWIRE
Immatics Announces Third Quarter 2023 Financial Results and Business Update
14 Nov 2023 //
GLOBENEWSWIRE
Immatics Reports Interim Clinical Data from ACTengine® IMA203
08 Nov 2023 //
GLOBENEWSWIRE
Immatics Receives FDA RMAT Designation for ACTengine® IMA203 TCR-T Monotherapy
24 Oct 2023 //
GLOBENEWSWIRE
Moderna, Immatics Ink Potential $1.8B Oncology Deal including Cancer Vaccines
12 Sep 2023 //
BIOSPACE
Immatics Announces Second Quarter 2023 Financial Results and Business Update
17 Aug 2023 //
GLOBENEWSWIRE
Immatics Initiates Phase 1/2 Trial to Evaluate PRAME TCR Bispecific IMA402
10 Aug 2023 //
GLOBENEWSWIRE
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
24 Jul 2023 //
GLOBENEWSWIRE
Immatics Announces First Quarter 2023 Financial Results and Business Update
16 May 2023 //
GLOBENEWSWIRE
Immatics` stock soars on PRAME prospect`s solid tumor data
03 May 2023 //
FIERCE BIOTECH
Immatics spikes on a round of promising but still early autologous cell therapy
02 May 2023 //
ENDPTS
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate
01 May 2023 //
GLOBENEWSWIRE
Immatics Announces Full Year 2022 Financial Results and Corporate Update
21 Mar 2023 //
GLOBENEWSWIRE
Immatics announces multiple pipeline changes with latest financial results
21 Mar 2023 //
ENDPTS
Immatics Falls Victim to GSK`s Receding Cell Therapy Pipeline
18 Nov 2022 //
BIOSPACE
Immatics Reports Data Update on ACTengine IMA203 TCR-T Monotherapy
11 Oct 2022 //
PRESS RELEASE
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
10 Oct 2022 //
GLOBENEWSWIRE
Immatics Presents Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME
09 Sep 2022 //
GLOBENEWSWIRE
Immatics finds a pan-cancer target for T-cell therapies
31 Aug 2022 //
FIERCEBIOTECH
Immatics Announces First Cancer Patient Treated with ACTengine TCR-T
23 Aug 2022 //
GLOBENEWSWIRE
Immatics Announces Second Quarter 2022 Financial Results and Business Update
09 Aug 2022 //
GLOBENEWSWIRE
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
20 Jul 2022 //
NASDAQ
Immatics, Editas Medicine Enter Research Collaboration and Licensing Agreement
07 Jun 2022 //
GLOBENEWSWIRE
Immatics & BMS Expand Alliance for Gamma Delta Allogeneic Cell Therapy Programs
02 Jun 2022 //
GLOBENEWSWIRE
Immatics Announces First Quarter 2022 Financial Results and Business Update
02 Jun 2022 //
GLOBENEWSWIRE
Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T
18 May 2022 //
GLOBENEWSWIRE
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401
10 May 2022 //
GLOBENEWSWIRE
Immatics Announces Full Year 2021 Financial Results and Corporate Update
23 Mar 2022 //
GLOBENEWSWIRE
BMS antes up on a $920M partnership play for a next-gen bispecific
15 Dec 2021 //
ENDPTS
Immatics & Bristol Myers Enter Into Global Exclusive License for Immatics IMA401
14 Dec 2021 //
GLOBENEWSWIRE
BMS doubles down on Immatics with new $770M biobucks collab
14 Dec 2021 //
FIERCEBIOTECH
Immatics touts positive early data for TCR-engineered cell therapy candidate
09 Nov 2021 //
FIRSTWORDPHARMA
Immatics unveils early-stage data for top contender to develop TCRs
09 Nov 2021 //
ENDPTS
Selexis, KBI Biopharma, Immatics Partner to Advance TCR Program
30 Jun 2021 //
CONTRACTPHARMA
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics IMA402
11 May 2021 //
GLOBENEWSWIRE
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine®
17 Mar 2021 //
GLOBENEWSWIRE
Immatics Announces Third Quarter 2020 Financial Results and Business Update
02 Dec 2020 //
GLOBENEWSWIRE
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101
10 Nov 2020 //
GLOBENEWSWIRE
Immatics Presents Preclinical Proof-of-Concept Data for TCR IMA401
29 Oct 2020 //
GLOBENEWSWIRE
Theolytics Announces Appointment Of Immatics` C. Reinhardt To Its BOD
20 Sep 2020 //
PRNEWSWIRE
Immatics Provides Update on IMA204 ACTengine Cell Therapy Program
10 Sep 2020 //
GLOBENEWSWIRE
Immatics identifies two TCR candidates for its IMA204 cancer program
09 Sep 2020 //
SEEKINGALPHA
Immatics Announces Second Quarter 2020 Financial Results and Business Update
03 Sep 2020 //
GLOBENEWSWIRE
